Source:http://linkedlifedata.com/resource/pubmed/id/20802128
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2010-11-1
|
pubmed:abstractText |
Myocardial infarction (MI) results in significant metabolic derangement, causing accumulation of metabolic by product, such as homocysteine (Hcy). Hcy is a nonprotein amino acid generated during nucleic acid methylation and demethylation of methionine. Folic acid (FA) decreases Hcy levels by remethylating the Hcy to methionine, by 5-methylene tetrahydrofolate reductase (5-MTHFR). Although clinical trials were inconclusive regarding the role of Hcy in MI, in animal models, the levels of 5-MTHFR were decreased, and FA mitigated the MI injury. We hypothesized that FA mitigated MI-induced injury, in part, by mitigating cardiac remodeling during chronic heart failure. Thus, MI was induced in 12-wk-old male C57BL/J mice by ligating the left anterior descending artery, and FA (0.03 g/l in drinking water) was administered for 4 wk after the surgery. Cardiac function was assessed by echocardiography and by a Millar pressure-volume catheter. The levels of Hcy-metabolizing enzymes, cystathionine ?-synthase (CBS), cystathionine ?-lyase (CSE), and 5-MTHFR, were estimated by Western blot analyses. The results suggest that FA administered post-MI significantly improved cardiac ejection fraction and induced tissue inhibitor of metalloproteinase, CBS, CSE, and 5-MTHFR. We showed that FA supplementation resulted in significant improvement of myocardial function after MI. The study eluted the importance of homocysteine (Hcy) metabolism and FA supplementation in cardiovascular disease.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Folic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Hematinics,
http://linkedlifedata.com/resource/pubmed/chemical/Homocysteine,
http://linkedlifedata.com/resource/pubmed/chemical/Matrix Metalloproteinases,
http://linkedlifedata.com/resource/pubmed/chemical/Tissue Inhibitor of...
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1522-1539
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
299
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
H1484-93
|
pubmed:dateRevised |
2011-11-1
|
pubmed:meshHeading |
pubmed-meshheading:20802128-Animals,
pubmed-meshheading:20802128-Dietary Supplements,
pubmed-meshheading:20802128-Folic Acid,
pubmed-meshheading:20802128-Heart,
pubmed-meshheading:20802128-Hematinics,
pubmed-meshheading:20802128-Homocysteine,
pubmed-meshheading:20802128-Male,
pubmed-meshheading:20802128-Matrix Metalloproteinases,
pubmed-meshheading:20802128-Mice,
pubmed-meshheading:20802128-Mice, Inbred C57BL,
pubmed-meshheading:20802128-Models, Animal,
pubmed-meshheading:20802128-Myocardial Infarction,
pubmed-meshheading:20802128-Myocytes, Cardiac,
pubmed-meshheading:20802128-Neovascularization, Physiologic,
pubmed-meshheading:20802128-Tissue Inhibitor of Metalloproteinases,
pubmed-meshheading:20802128-Treatment Outcome,
pubmed-meshheading:20802128-Ventricular Function, Left
|
pubmed:year |
2010
|
pubmed:articleTitle |
Folic acid mitigated cardiac dysfunction by normalizing the levels of tissue inhibitor of metalloproteinase and homocysteine-metabolizing enzymes postmyocardial infarction in mice.
|
pubmed:affiliation |
Department of Physiology and Biophysics, School of Medicine, University of Louisville, Louisville, Kentucky 40202, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|